Skip to search formSkip to main contentSkip to account menu

guselkumab

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Monoclonal Antibodies

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Evaluating Potential Disease‐Mediated Protein‐Drug Interactions in Patients With Moderate‐to‐Severe Plaque Psoriasis Receiving Subcutaneous Guselkumab
This open‐label, multicenter, phase I therapeutic protein‐drug interaction study was designed to evaluate the potential effect of… 
2020
2020
Cost per responder analysis of guselkumab versus targeted therapies in the treatment of moderate to severe plaque psoriasis in Germany
Abstract Background The fully human monoclonal antibody guselkumab is an effective treatment option for patients with moderate to… 
Review
2020
Review
2020
Assessing the Short-Term Efficacy and Safety of Guselkumab for Moderate-to-Severe Plaque Psoriasis: Meta-Analysis of Randomized Controlled Trials
Background To investigate the efficacy and safety of guselkumab in the treatment of moderate-to-severe plaque psoriasis. Methods… 
Review
2019
Review
2019
Guselkumab for the treatment of adults with moderate to severe plaque psoriasis
ABSTRACT Introduction: Guselkumab is a subcutaneously administered monoclonal antibody that targets the IL-23p19 cytokine subunit… 
2019
2019
THU0052 USTEKINUMAB AND GUSELKUMAB TREATMENT RESULTS IN DIFFERENCES IN SERUM IL17A, IL17F AND CRP LEVELS IN PSORIATIC ARTHRITIS PATIENTS: A COMPARISON FROM USTEKINUMAB PH3 AND GUSELKUMAB PH2 PROGRAMS
Background: Ustekinumab (UST) is a monoclonal antibody (mAb) that binds the p40 epitope which is shared by IL12 and IL23, whereas… 
2019
2019
Maintenance of Response With up to 4 Years of Continuous Guselkumab Treatment: Results From the VOYAGE 1 Phase 3 Trial
Abstract not available. 
2019
2019
SAT0390 GUSELKUMAB WAS MORE EFFECTIVE THAN SECUKINUMAB IN PATIENTS WITH PLAQUE PSORIASIS AND THE SUBSET OF PATIENTS WITH SELF-REPORTED PSORIATIC ARTHRITIS IN THE RANDOMIZED, DOUBLE-BLIND, HEAD-TO…
Background Guselkumab (GUS, an antibody against IL-23) and secukinumab (SEC, an antibody against IL-17A) are both approved for… 
2018
2018
Safety and efficacy of guselkumab in Japanese patients with moderate‐to‐severe plaque psoriasis: a randomized, placebo‐controlled, ascending‐dose study
The interleukin (IL)‐23/IL‐17 pathway is central in the pathogenesis of psoriasis. The favourable efficacy and safety of… 
Review
2018
Review
2018
Targeting p19 as a treatment option for psoriasis: an evidence-based review of guselkumab
Further understanding of psoriasis pathogenesis has led to the development of effective biologic medications. Guselkumab (GUS) is… 
Review
2018
Review
2018
Treating Moderate-to-Severe Plaque Psoriasis With Guselkumab: A Review of Phase II and Phase III Trials
Objective: Guselkumab, an anti-interleukin-23 monoclonal antibody was recently approved for the treatment of patients with… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)